About adagene - ADAG
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.
ADAG At a Glance
Adagene, Inc.
Suzhou Industrial Park
Suzhou, Jiangsu 215123
| Phone | 86-512-8777-3632 | Revenue | 7.69M | |
| Industry | Pharmaceuticals: Major | Net Income | -17,655,985.24 | |
| Sector | Health Technology | 2025 Sales Growth | 7,348.678% | |
| Fiscal Year-end | 12 / 2026 | Employees | 128 | |
| View SEC Filings |
ADAG Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 11.60 |
| Price to Book Ratio | 2.534 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.794 |
| Enterprise Value to Sales | 4.877 |
| Total Debt to Enterprise Value | 0.167 |
ADAG Efficiency
| Revenue/Employee | 60,087.418 |
| Income Per Employee | -137,937.385 |
| Receivables Turnover | 443.32 |
| Total Asset Turnover | 0.092 |
ADAG Liquidity
| Current Ratio | 3.074 |
| Quick Ratio | 3.074 |
| Cash Ratio | 2.961 |
ADAG Profitability
| Gross Margin | 92.425 |
| Operating Margin | -279.475 |
| Pretax Margin | -233.444 |
| Net Margin | -229.561 |
| Return on Assets | -21.073 |
| Return on Equity | -34.476 |
| Return on Total Capital | -30.356 |
| Return on Invested Capital | -33.897 |
ADAG Capital Structure
| Total Debt to Total Equity | 12.068 |
| Total Debt to Total Capital | 10.768 |
| Total Debt to Total Assets | 8.001 |
| Long-Term Debt to Equity | 3.371 |
| Long-Term Debt to Total Capital | 2.049 |